Antimex Chemical Limied
Country: China (Mainland)
Year Established: 2001
Business type: Lab/Research institutions
Contact Details | Similar Products

Communicate with Supplier:

: Mr. Tony: What can I do for you?

126784-99-4 discount high purity Ulipristal Acetate factory CAS NO.126784-99-4

FOB Price:: USD 15.00-15.00 /Gram Get Latest Price

Min.Order Quantity:: 1 Gram

Purity:: 99%

Port:: Chinese main port

Payment Terms:: T/T,Other

Add to Inquiry Cart

Product Details

Keywords

Ulipristal Acetate factory
126784-99-4 high purity
126784-99-4 discount

Quick Details

ProName: 126784-99-4 discount high purity Uli...
CasNo: 126784-99-4
Molecular Formula: C28H35NO3
Appearance: detailed see specifications
Application: An important raw material and intermed...
DeliveryTime: 2weeks
PackAge: 25kg/drum;200kg/drum
Port: Chinese main port
ProductionCapacity: 10 Kilogram/Month
Purity: 99%
Storage: Keep away of light, cool place
Transportation: By Sea/air/courier
LimitNum: 1 Gram
Grade: Pharma Grade
Purity: 98%

Superiority

126784-99-4 discount high purity ulipristal acetate factory

grademedicine grade

hs code29339900

physical formpowder

molecular formulac30h37no4

cas no126784-99-4

melting point183-188 dec

shelf life2 years

molecular weight475.62 grams (g)

usagepharmaceutical intermediates

purity(%)99

typepharmaceutical intermediates

appearancewhite powder

loss on dryinga 0.5%

structural formulac30h37no4

storageroom temperature

chemical name(11b)-17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione

heavy metal (%)a 10ppm

smellno smell

einecs no682-170-1

tasteodorless

medicine nameulipristal acetate

certificationsiso9001

delivery time1 week

main export market(s)north america, africa, south america, central america, western europe, asia

fob portany port in china

sample policywithin a certain price range free samples are available

packaging detailsas per request

payment termsletter of credit at sight (sight l/c), cash in advance (cid), days after acceptance (da), cash against delivery (cad), paypal

supply ability100 per month

main domestic marketall india

offered byshijiazhuang dingmin pharmaceutical sciences co., ltd.

product added onsep 11, 2019

last updated onfeb 03, 2020

branddm

antimex group, was founded in 2001,we are specializing in manufacturing & researching, warehouse & logistics of active pharmaceutical ingredients, pharmaceutical and chemical raw materials, veterinary pharm apis, food and feed additives,chelate agent, organo silane,dcdfs(dichlorodiphenylsilane) and water treatment chemicals calcium hipochlorite 65% and 70%. some intermediate including da-6, naa, iba, iaa, 6-ba, cppu, compound sodium nitrophenolate, 1-mcp，pharm intermediate and we can supply new products which custom synthesis required, our markets cover all over the world,with the annual turnover of more than 10million dollars.

we also distribute food and feed additives,silicone monomer and water treatment chemicals,like calcium hipochlorite 65% and 70%,pac,dcdfs(dichlorodiphenylsilane),apg08-10,apg12-14.etc.advanced production equipments, professional technology, long-years marketing experiences and excellent service team, ensure that we have got good reputations from the customers from europe, america and middle east, southeast asia, all over the world.

as an advancing company, antimex people sincerely hopes to build up a brilliant future with our friends at home and abroad! welcome contact us freely!

Details

ulipristal acetate basic information

oral emergency contraception pharmacological action pharmacokinetics market prospect intellectual property rights other clinical researches

product name:	ulipristal acetate
synonyms:	hrp 2000;(11b)-17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione;cbd 2914;va 2914;ulipristal;ulipristal acetate;ulipristal acetate/cdb2914;17α-acetoxy-11β-(4-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione
cas:	126784-99-4
mf:	c28h35no3
mw:	433.5824
einecs:
product categories:	api;aromatics;intermediates & fine chemicals;isotope labelled compounds;pharmaceuticals;steroids;final material;inhibitors
mol file:	126784-99-4.mol

ulipristal acetate chemical properties

mp	183-185 ºc
density	1.19

safety information

msds information

ulipristal acetate usage and synthesis

oral emergency contraception	ulinastal acetate is a new oral contraceptive pill, and it is the active chemical composition of ella, a new generation of emergency contraceptive wildly on the market in united states currently. it can protect women within 120 hours after intercourse without medication, and the emergency contraceptive efficacy will not decline with the delay of treatment time. at the same time, it is safe and durable. compared with the most commonly used emergency contraceptive levonorgestrel, ulinastal acetate is more suitable for clinical use, and has the potential to prevent more unwanted pregnancies. ulipristal acetate was developed by hra pharmaceuticals, inc., and was marketed by the food and drug administration (fda) in august 2010 under the trade name ella. it could be used for the protection of unprotected sex or for the pregnancy prevention in the known or suspected contraceptive failure situation within 120h. ulipristal acetate is a selective progesterone receptor modulator; and mainly it can take effect by inhibiting the ovulation and plays an emergency contraceptive effect. the study found that ulastatal acetate was more effective than levonorgestrel in suppressing vomiting after dosing before the estimated ovulation day. and it consequently suggests that ulatastatin acetate might have a stronger emergency contraceptive effectiveness. figure 1 for the structure of ulcaritin acetate
pharmacological action	ulinastal acetate is a progesterone agonist / antagonist that inhibits or delays the ovulation; however, changes in the endometrium may also be a cause of efficacy. ulinastal acetate belongs to the category of selective progesterone receptor modulator, and it has partial agonistic action to progesterone receptor antagonism and partial agonism. it binds to progesterone receptors in the human body and prevents progesterone receptor binding. the efficacy of ulinastal acetate depends on the time of administration in the menstrual cycle. administration during the mid-follicular hyperplasia would suppress follicle formation and decrease the estradiol concentrations. and the administration during the in the peak period of follicular hyperplasia can delay the breakdown of follicles from 5 to 9 days. although early luteal phase of administration cannot significantly delay the endometrial maturation, it can reduce the thickness of the endometrium within 0.6±2.2mm（average value ±sd）.
pharmacokinetics	absorption: the highest fasting plasma concentrations of 20 women reached 176 ng/ ml and 69ng/ ml after 0.9 and 1 hour of using ulipristal acetate and active metabolite (mono-demethyl-ulipristal acetate) in single bolus medication. and mono palmitoyl-ulipristal acetate was lower by 40% to 45% compared with the high-fat breakfast. and ompared with the fasting state, and the delayed tmax (delayed from median 0.75 h to 3 h) with an average auc0-∞ of 20% to 25% higher. these differences are not expected to impair the efficacy or safety of ulinastal acetate. therefore, ulatastatin acetate can take effect in both situation: with or without food. distribution: this product has a high binding rate (> 94%) with plasma protein, high-density lipoprotein, α-1-acid glycoprotein and albumin. metabolism: ulipristal acetate could be metabolized to mono-desmethyl and bis-nor-metabolites. in vitro data indicates that single demethyl metabolites are pharmacologically active, mainly due to cyp3a4 mediated. excretion: the terminal half-life of ulipristal acetate in plasma after a single dose of ulistatta 30 mg would be estimated to (32.4 ± 6.3) hours. the pharmacological effects, pharmacokinetics, market prospect and patent intellectual property rights of oral emergency contraceptive ulinastal acetate were edited by xiao nan from chemical book.
market prospect	emergency contraception, also known as after-birth control pills, is a kind of contraceptive for women of childbearing age in the situation od non-protective intercourse or contraceptive failure after the use of contraception to prevent accidental pregnancy. at present, the most widely used emergency contraceptive is levonorgestrel (1evonorgestre1), which is used at intervals of 12hours each serving one piece (0.75mg) or a single taking of two pieces(1.5mg). however, levonorgestrel was only approved for using as an emergency contraceptive only 72 hours (3days) after unprotected intercourse or contraceptive failure. even though, the efficacy of levonorgestrel emergency contraception will be significantly reduced with the delay of treatment time; it is recommended that it should better used in unprotected intercourse or contraceptive failure within 12h after the start of medication. in may 2009, the european union approved a new emergency contraceptive ulipristal acetate, also called as ella one, which is not only allowed to be taken within 120 hours (5 days) of unprotected intercourse or contraceptive failure, but the emergency contraceptive efficacy would not delay and decline with the medication time. ulastat is one of the first oral contraceptives approved worldwide to be administered within 120 hours of unprotected intercourse or contraceptive failure, which has the potential to prevent more unwanted pregnancies than levonorgestrel. as a new oral emergency contraceptive, ulinastal acetate can not only be used within 120 hours after unprotected intercourse, but the efficacy of emergency contraception would not decrease with the delay of administration, and it is safe and durable as well. compared with the most commonly used emergency contraceptive levonorgestrel, ulinastal acetate is more suitable for clinical use, and it has the potential to prevent more unwanted pregnancies.
intellectual property rights	the original research manufacturer in china has already applied for a patent for ulinastal acetate tablets and its indications as well as for its indications. however, it has not been authorized yet. there are not any intellectual property barriers.
other clinical researches	february 2, 2012, the new england journal of medicine published two clinical trials found that ulinastal acetate has an excellent effect in the treatment of uterine fibroids. the results show that ulinastal acetate is as effective as leuprolide in controlling uterine fibroid bleeding, reducing the volume of myoma and comforting the pain; according to statistics, about a quarter of women have suffered from uterine fibroids symptoms. leuprolide acetate, a gonadotropin-releasing hormone (gnrh) agonist, has been approved for preoperative treatment of uterine fibroids since its approval in 1995. ulinastal acetate can successfully challenge leuprolide and it becomes become a new choice for preoperative uterine fibroids drug therapy. let’s wait for the post-trial to reveal the answer.
chemical properties	pale yellow solid
usage	α selective labelled progesterone receptor modulator
usage	ulipristal acetate is a selective progesterone receptor modulator
usage	labelled ulipristal